imiglucerase: Clinical Trials

8 trials of imiglucerase, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1
Phase 21Withdrawn 1

Follow imiglucerase: new trials by email Literature Review of imiglucerase trials Research Report on imiglucerase

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3
Phase 2 / Phase 3WithdrawnAVROBIO2023-10-012023-08-09
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
Venglustat, imiglucerase - Gaucher's Disease Type III
Phase 3Active not recruitingSanofi432022-04-182026-07-13
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
Eliglustat GZ385660, Imiglucerase GZ437843 - Gaucher's Disease Type I, Gaucher's Disease Type III
Phase 3CompletedSanofi572018-04-112026-06-16
Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
ISU302 - Gaucher Disease, Type 1
Phase 3CompletedISU Abxis Co., Ltd.82011-09-012017-07-12
The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease
Cerezyme®, ISU302 - Gaucher Disease
Phase 3WithdrawnISU Abxis Co., Ltd.2011-01-012016-08-23
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Eliglustat tartrate, Imiglucerase - Gaucher Disease, Type 1
Phase 3CompletedGenzyme, a Sanofi Company1602009-09-012016-11-25
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
velaglucerase alfa, imiglucerase - Gaucher Disease, Type 1
Phase 3CompletedShire342008-01-292021-06-08

Conditions studied

Gaucher Disease (8)

Sponsors

Sanofi (3)  ·  ISU Abxis Co., Ltd. (2)  ·  AVROBIO (1)  ·  Genzyme, a Sanofi Company (1)  ·  Shire (1)

Countries

Argentina (4)  ·  United Kingdom (4)  ·  Canada (3)  ·  France (3)  ·  Italy (3)  ·  Russia (3)  ·  Spain (3)  ·  United States (3)  ·  Germany (2)  ·  Japan (2)  ·  Turkey (Türkiye) (2)  ·  Australia (1)  ·  Brazil (1)  ·  China (1)  ·  Egypt (1)

Top investigators

Amel El Beshlawy, Prof. (1)  ·  Milena Veselinovic, MD, PhD (1)

Results publications

PMID 25819691, PMID 27839979, PMID 28167660

NIH funding

2008 (1), 2016 (1)